关于举行南洋理工学院张华教授学术报告会的通知,IGCP567地震考古研究项目最新动态消息

IGCP5陆七地震考古切磋项目最新动态消息

“目录号: HY-14171

告诉标题:Phase Engineering of Novel Nanomaterials报 告
人:张华教授告诉时间:二〇一八年7月10日1陆:00-17:30报告地点:华南理工科业大学学大学城校区B肆-21伍会议室应接广大师生前往参加!情形与财富大学二〇一八年10月1二二十13日告知摘要:In
this talk, I will summarize the recent research on the phase engineering
of nanomaterials in my group. It includes the first-time synthesis of
hexagonal-close packed (hcp) Au nanosheets (AuSSs) on graphene oxide,
the first-time synthesis of 四H hexagonal phase Au nanoribbons (NRBs),
the synthesis of crystal-phase heterostructured 肆H/fcc Au nanorods, the
epitaxial growth of metals with novel phases on the aforementioned Au
nanostructures, and the synthesis of amorphous/ crystalline hetero-phase
Pd nanosheets. In addition, the first-time synthesis of 1T’-MoS2 and
壹T’-MoSe二 crystals have been achieved. Moreover, the phase
transformation of transition metal dichalcogenide nanomaterials during
our developed electrochemical Li-intercalation method will also be
introduced. Interestingly, the lithiation-induced amorphization of
Pd三P二S8 is also achieved. Currently, my group focuses on the (crystal)
phase-based properties and applications in catalysis, 三星平板 enhanced
拉曼 scattering, waveguide, photothermal therapy, chemical and
biosensing, clean energy etc., which we believe are quite unique and
very important not only in fundamental studies, but also in practical
applications. Importantly, the concepts of crystal-phase
heterostructures and hetero-phase nanomaterials are proposed.Keywords:
Crystal Phase; Noble Metal Nanomaterials; Hexagonal-Close Packed;
Face-Centered Cubic; 高尔德; Ultrathin Nanosheets; Transition Metal
Dichalcogenides报告人简单介绍:Dr. Hua Zhang obtained his B.S. and M.S.
degrees at Nanjing University in China in 一九九二 and 壹玖九一, respectively,
and completed his Ph.D. with Prof. Zhongfan Liu at Peking University in
China in July 一玖九七. He joined Prof. Frans C. De Schryvers group at
Katholieke Universiteit Leuven (KULeuven) in Belgium as a Research
Associate in January 一九九7. Then he moved to Prof. Chad A. Mirkins group
at Northwestern University as a Postdoctoral Fellow in July 200壹. He
started to work at NanoInk Inc. (USA) as a Research Scientist/Chemist in
奥古斯特 2003. After that, he worked as a Senior Research Scientist at
Institute of Bioengineering and Nanotechnology in Singapore from
November 200五 to July 2006. Then he joined the School of Materials
Science and Engineering in Nanyang Technological University (NTU) as an
Assistant Professor. He was promoted to a tenured Associate Professor on
March 壹, 201一, and Full Professor on Sept. 壹, 201三. Dr. Zhangs research
is highly interdisciplinary. His current research interests focus on the
(crystal-)phase engineering of nanomaterials and controlled epitaxial
growth of heterostructures, including the synthesis of ultrathin
two-dimensional nanomaterials (e.g. metal nanosheets, graphene, metal
dichalcogenides, metal-organic frameworks, covalent organic frameworks,
etc.), novel metallic and semiconducting nanomaterials, novel amorphous
nanomaterials and their hybrid composites, for various applications such
as catalysis, clean energy, (opto-)electronic devices, nano- and
biosensors, and water remediation.He has published 伍 invited book
chapters, 73 patent applications (including 八 granted US patents and 一Singapore patent), and over 450 papers, among which 20三 papers were
published in IF>10 journals and 十3 papers were published in 八journals. Some of his papers have been published in Science (1), Nat.
Chem. (伍), Nat. Catal. (一), Nat. Rev. Mater. (贰), Nat. Commun. (八), Sci.
Adv. (一), Nat. Protocols (1), Chem. Rev. (贰), Chem. Soc. Rev. (1二), Acc.
Chem. Res. (二), J. Am. Chem. Soc. (1陆), Angew. Chem. Int. 艾德. (28), Adv.
Mater. (51), Chem (一), Energy Environ. Sci (1贰), Mater. Today (壹), Adv.
Energy Mater. (六), ACS Nano (2玖), Nano Lett. (1四), Adv. Funct. Mater.
(四), Nano Energy (4), Mat. Horizons (二), ACS Catal. (一), etc. Based on
Web of Science on Dec. 0二, 201八, the total citation times of his papers
are over 5三,900 with H-index of 11五. He has been invited to give more
than 300 Plenary, Keynote or Invited Talks in international conferences,
universities and institutes, and serve as the Session Chair. He has
organized several tens of international conferences and served as the
Symposium Chair or Conference Co-Chair. He is one of three Chairmen of
the 艾德itorial Board of ChemNanoMat (201伍-), sits on the Advisory Board
of Chem. Soc. Rev. (二〇一一-), Materials Chemistry Frontiers (201陆-),
马特er (2019-), Nanoscale (二零一三-), Nanoscale Horizons (20壹5-) and NPG
Asia Materials (201八-), the 艾德itorial Advisory Board of ACS Nano
(201四-), ACS Appl. Mater. Interfaces (201四-), Advanced Functional
Materials (201八-), Chem. Mater. (201四-), Nanofabrication (2013-) and
Small (二〇一一-), the 艾德itorial Board of ACS Omega (2016-), Applied
Materials Today (20一伍-), Carbon (20壹三-), CHEM (二〇一四-), Chinese Science
Bulletin (201四-), Energy Storage Materials (20壹伍-), EnergyChem (2018-),
Graphene Technology (201六-), Materials Today Energy (201陆-), NANO
(2006-), npj 贰D Materials and Applications (201陆-) and Science China
Materials (2014-), and the International Advisory Board of Materials
Research Express (201四-二零一六) and ChemPlusChem (二零一三-20一伍). He is also
one of the members of the Advisory Committee of IOP Asia-Pacific
(200九-). In 2016, he was elected as an Academician of the Asia Pacific
Academy of Materials (APAM). In Nov. 201四, he was elected as a Fellow of
the 罗伊al Society of Chemistry (FLANDSC). In 贰零一4, he was listed in the top
300 most cited researchers in the 田野(field) of materials science and
engineering (Elsevier Scopus). In 201伍-201八, he was listed in the
“Highly Cited Researchers” in Chemistry and Materials Science (ThomsonReuters). In 20一5, he was listed as one of 1玖 Hottest Researchers of
Today in the world in the Worlds Most Influential Scientific Minds 2014(汤姆森 Reuters, 20一伍). In 201四, he was listed in the “Highly Cited
Researchers 201四” in Materials Science, and also listed as one of 17Hottest Researchers of Today and No. 1 in Materials and More in the
world in the Worlds Most Influential Scientific Minds 201四 (ThomsonReuters, 201四). Moreover, he got the Young Investigator Award (Young
Giants of Nanoscience 二零一四, Hong Kong), Vice-Chancellors International
Scholar Award (University of Wollongong, Australia, 2016), ACS Nano
Lectureship Award (20一五), World Cultural Council (WCC) SpecialRecognition Award (201三), the ONASSIA Foundation Lectureship (Greece,
20一三), Asian Rising Stars (15th Asian Chemical Congress, 20一3), SMALL
Young Innovator Award (Wiley-VCH, 二零一三) and Nanyang Award for Research
Excellence (2011).附属类小部件:无

应接有对于地震考古切磋和喇家遗址远古地震感兴趣的青春情侣随即与大家关系

Metabolic
Enzyme/ProteaseAutophagy-

 

Bexarotene (Targretin)是维甲酸X受体(途乐X帕杰罗)激动剂,可职能于CTCL。

 

RAR/RXRAutophagy

MEETINGS

有关制品

· On 22 February 2012 IGCP will celebrate its 40th
Anniversary
at the UNESCO
Headquarters in Paris. Two of our co-leaders will actively participate
at this meeting. Iain Stewart (University of Plymouth, U.K.) will focus
on the importance of Geosciences for Society and moderate a debate on
the prospective vision for the future of IGCP. Manuel Sintubin
(Katholieke Universiteit Leuven, Belgium) will reflect on the role of
IGCP in geohazard mitigation
based on the success of IGCP567.

Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB
203580-SP600125-U0126-Enzalutamide-Actinomycin
D-Olaparib-Doxorubicin
hydrochloride-Dorsomorphin
dihydrochloride-Mitomycin
C-Bortezomib-

 

生物活性

·At the 2012 Annual Meeting of the Seismological Society of
America
(17-19 April, 2012,
San Diego, California): Earthquakes and Tsunamis at Caostal
Archaeological Sites
. You find details in the following announcement
(pdf
). Abstract submission deadline is 11 January
2012
.

Description

 

Bexarotene (Targretin) is a selective RXR agonist approved for the
treatment of CTCL.IC50 value:Target: retinoid X receptorExposure of
NSCLC cell lines to bexarotene as a single agent had modest growth
inhibitory effects (at > 1 μM). However, exposure of several NSCLC
lines to bexarotene (1–3 μM) produced significant decreases in the
expression of EGFR, Her-2 and TGF mRNA and protein. EGF levels were also
decreased to a much lesser degree.

·At the 34th International Geological
Congress (IGC)
, from 2 to 10
August 2012
at Brisbane, Queensland, Australia a special session is
convened by Patrick Nunn (Australia), Bruce McFadgen (New Zealand), Iain
Stewart (U.K.) and Manuel Sintubin (Belgium) on Natural Hazards and
Ancient
Societies
.
Abstract submission deadline is 17 February 2012.

Clinical Trial

 

NCT00153842

·In November 2012 we are furthermore planning an international workshop
Shakin’ them off? Interdisciplinary perspectives on Minoan
Earthquakes
, convened by Simon Jusseret (Université Catholique de
Louvain, Belgium) and Manuel Sintubin (Katholieke Universiteit Leuven,
Belgium), which will take place in Leuven (Belgium).

Dartmouth-Hitchcock Medical Center-Bristol-Myers Squibb-Ligand
Pharmaceuticals

 

Carcinoma, Non-small-cell Lung

For both conferences IGCP567 will most probably (depending on our
funding) be able to offer travel grants.

August 2001

 

Phase 1-Phase 2

·At the EGU meeting (20-24 April
2012, Vienna, Austria) Matthieu Ferry (Géosciences Montpellier, France)
and Kris Vanneste (ROB, Belgium) convene a session on Earthquake
Geology
.
Abstract submission deadline is 17 January 2012.

NCT00615784

 

Abramson Cancer Center of the University of Pennsylvania

·The 3rd Workshop on Paleoseismology and
Archaeoseismology

will be held in Morelia, Mexico from 1 to 8 November 2012.
More information will follow soon on the
http://www.acambay1912.org.

Acute Myeloid Leukemia

 

January 2008

PUBLICATIONS

Phase 2

 

NCT01504490

Following our 2nd INQUA-IGCP567 International Workshop on
Active Tectonics, Earthquake Geology, Archaeology and
Engineering
,
held from 18 to 24 September 2011 in Corinth, Greece, Andreas Vött
(University of Mainz, Germany) is preparing a special volume on in the
Zeitschrift für Geomorphologie. This is a peer-review ISI-indexed
journal and hosted up to now three special volumes on tsunamis. If you
are interested to contribute to this volume, please contact Andreas Vött
(voett@uni-mainz.de).

Georgetown University-Daiichi Sankyo Inc.

 

Solid Tumors-Lymphoma-Multiple Myeloma

International Geoscience Programme
IGCP 567 Earthquake Archaeology

December 2011

De wetenschap van de Aarde. Over een levende
planeet

Phase 1


NCT00125372

 

Dartmouth-Hitchcock Medical Center-Ligand Pharmaceuticals-Genentech,
Inc.

Disclaimer:

Carcinoma, Non-small-cell Lung

December 2005

NCT00845351

University of Virginia

Cushing’s Disease

November 2008

Phase 1-Phase 2

NCT01782742

The Cleveland Clinic

Alzheimer’s Disease

February 2013

Phase 2

NCT01116622

Dartmouth-Hitchcock Medical Center-Genentech, Inc.-Ligand
Pharmaceuticals

Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and
Esophagus)

April 2003

Phase 1

NCT00055991

Baylor Breast Care Center-National Cancer Institute (NCI)

Breast Cancer

September 2001

Phase 1

NCT00125359

Dartmouth-Hitchcock Medical Center-Ligand Pharmaceuticals-Genentech,
Inc.

Carcinoma, Non-small-cell Lung

August 2005

Phase 2

NCT02061878

ReXceptor, Inc.

Alzheimer’s Disease

August 2014

Phase 1

NCT01007448

Valeant Pharmaceuticals International, Inc.

Refractory Cutaneous T-cell Lymphoma

December 2009

Phase 4

NCT00660231

University College, London

Lymphoma

March 2008

Phase 2

NCT01001143

Washington University School of Medicine

Leukemia, Myeloid, Acute

May 2010

Phase 1

NCT00316030

Abramson Cancer Center of the University of Pennsylvania

AML-Acute Myeloid Leukemia

January 2004

Phase 1

NCT00411632

M.D. Anderson Cancer Center-United States Department of Defense

Lung Cancer

November 2006

Phase 2

NCT00306969

Boston University-Ligand Pharmaceuticals

Cutaneous T-Cell Lymphoma

December 2001

Phase 1-Phase 2

NCT00535574

Beersheva Mental Health Center

Schizophrenia

November 2008

Phase 3

NCT01578499

Millennium Pharmaceuticals, Inc.-Seattle Genetics, Inc.-Takeda

Primary Cutaneous Anaplastic Large Cell Lymphoma-Mycosis
Fungoides-Cutaneous T-Cell Lymphoma

August 2012

Phase 3

NCT00255801

Memorial Sloan Kettering Cancer Center-National Cancer Institute
(NCI)-Tibotec Pharmaceutical Limited-M.D. Anderson Cancer Center-New
York University School of Medicine-Hackensack University Medical
Center-Roswell Park Cancer Institute

Lymphoma

November 2005

Phase 2

NCT00178841

Vanderbilt University

Cutaneous T-cell Lymphoma-Mycosis Fungoides-Sezary Syndrome

June 2005

Phase 2

NCT00141947

Beersheva Mental Health Center-Stanley Medical Research Institute

Schizophrenia

September 2005

Phase 3

NCT00151008

University of Medicine and Dentistry of New Jersey-Ligand
Pharmaceuticals-Rutgers, The State University of New Jersey

Psoriasis

November 2003

Phase 2

NCT01134341

Spectrum Pharmaceuticals, Inc

Cutaneous T-cell Lymphoma-Mycosis Fungoides-Sezary Syndrome-Primary
Cutaneous Anaplastic Large Cell Lymphoma

March 2010

Phase 1

NCT00322296

Fox Chase Cancer Center-Ligand Pharmaceuticals

Parapsoriasis

April 2001

Phase 2

NCT00003752

Ligand Pharmaceuticals-National Cancer Institute (NCI)

Breast Cancer

October 1998

Phase 2

NCT00056056

European Organisation for Research and Treatment of Cancer – EORTC

Lymphoma

January 2003

Phase 3

NCT00127101

Merck Sharp & Dohme Corp.

Lymphoma

September 2005

Phase 1

NCT00718770

University of Colorado, Denver-American Cancer Society, Inc.-Eisai Inc.

Thyroid Cancer

November 2008

Early Phase 1

NCT00050960

Eisai Inc.

Non-small Cell Lung Cancer

May 2002

Phase 3

NCT00050973

Eisai Inc.

Non-small Cell Lung Cancer

Phase 3

NCT00238628

Stanford University-Ligand Pharmaceuticals-AstraZeneca

Lung Cancer

April 2004

Phase 1-Phase 2

NCT00030849

Memorial Sloan Kettering Cancer Center-National Cancer Institute (NCI)

Lymphoma

October 2001

Phase 2

NCT00534898

Beersheva Mental Health Center

Schizophrenia-Schizoaffective Disorder-Cognition

Phase 3

NCT00002212

Ligand Pharmaceuticals-NIH AIDS Clinical Trials Information Service

Sarcoma, Kaposi-HIV Infections

Phase 2

NCT00425477

Sidney Kimmel Comprehensive Cancer Center-National Cancer Institute
(NCI)

Leukemia-Myelodysplastic Syndromes-Myelodysplastic/Myeloproliferative
Diseases

November 2006

Phase 2

NCT00514293

Raghu Nandan, M.D., Inc-National Cancer Institute (NCI)

Lung Cancer

January 2007

Phase 2

NCT00030589

Millennix-National Cancer Institute (NCI)

Lymphoma

February 2001

Phase 2

NCT00153842

Dartmouth-Hitchcock Medical Center-Bristol-Myers Squibb-Ligand
Pharmaceuticals

Carcinoma, Non-small-cell Lung

August 2001

Phase 1-Phase 2

NCT00615784

Abramson Cancer Center of the University of Pennsylvania

Acute Myeloid Leukemia

January 2008

Phase 2

NCT01504490

Georgetown University-Daiichi Sankyo Inc.

Solid Tumors-Lymphoma-Multiple Myeloma

December 2011

Phase 1

NCT00125372

Dartmouth-Hitchcock Medical Center-Ligand Pharmaceuticals-Genentech,
Inc.

Carcinoma, Non-small-cell Lung

December 2005

NCT00845351

University of Virginia

Cushing’s Disease

November 2008

Phase 1-Phase 2

NCT01782742

The Cleveland Clinic

Alzheimer’s Disease

February 2013

Phase 2

NCT01116622

Dartmouth-Hitchcock Medical Center-Genentech, Inc.-Ligand
Pharmaceuticals

Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and
Esophagus)

April 2003

Phase 1

NCT00055991

Baylor Breast Care Center-National Cancer Institute (NCI)

Breast Cancer

September 2001

Phase 1

NCT00125359

Dartmouth-Hitchcock Medical Center-Ligand Pharmaceuticals-Genentech,
Inc.

Carcinoma, Non-small-cell Lung

August 2005

Phase 2

NCT02061878

ReXceptor, Inc.

Alzheimer’s Disease

August 2014

Phase 1

NCT01007448

Valeant Pharmaceuticals International, Inc.

Refractory Cutaneous T-cell Lymphoma

December 2009

Phase 4

相关文章

发表评论

电子邮件地址不会被公开。 必填项已用*标注